Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/1471-0528.16240 | DOI Listing |
Biomedicines
August 2024
Departmental Faculty of Medicine, Saint Camillus International University of Health Sciences, Via di Sant'Alessandro 8, 00131 Rome, Italy.
The primary intervention for pre-eclampsia (PE) remains iatrogenic delivery, which can be very preterm and not optimal for the fetus. Although many efforts have been made to prevent and manage PE, there is still a dearth of drugs to treat its pathophysiological progression. Pravastatin (PRA), a hydrophilic statin, has gained interest for the prevention and treatment of PE.
View Article and Find Full Text PDFEur Heart J
August 2023
Division of Medical Genetics, Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, 6431 Fannin Street, Houston, TX 77030, USA.
Aims: The variant p.Arg149Cys in ACTA2, which encodes smooth muscle cell (SMC)-specific α-actin, predisposes to thoracic aortic disease and early onset coronary artery disease in individuals without cardiovascular risk factors. This study investigated how this variant drives increased atherosclerosis.
View Article and Find Full Text PDFEur Rev Med Pharmacol Sci
November 2022
Division of Respiratory Medicine, Digestive Internal Medicine, The First People's Hospital of Fuyang Hangzhou, Hangzhou, China.
Objective: Asthma is a chronic airway inflammatory disease caused by high infiltration of multiple inflammatory cells and factors in airway tissues. Statins may inhibit inflammation, hence improve asthma symptoms. This meta-analysis aimed to assess the efficacy of statins in the treatment of asthma patients.
View Article and Find Full Text PDFJ Vasc Res
December 2021
Department of Obstetrics and Gynaecology, Tampere University Hospital, Tampere, Finland.
Objective: To determine the direct effect of pravastatin on angiogenesis and to study the interaction between pravastatin and maternal sera from women with early- or late-onset pre-eclampsia (PE), intrauterine growth restriction, or healthy pregnancy.
Methods: We collected 5 maternal serum samples from each group. The effect of pravastatin on angiogenesis was assessed with and without maternal sera by quantifying tubule formation in a human-based in vitro assay.
Vascul Pharmacol
April 2021
College of Medicine, QU Health, Qatar University, Qatar. Electronic address:
Background: Uteroplacental vascular dysfunction, characterized by diminished uterine artery (UtA) blood flow in the second trimester is a clinically useful predictor of the further development of preeclampsia, fetal growth restriction and stillbirth. Efforts to develop effective treatments to protect pregnancies with abnormal UtA Dopplers would be of significant clinical benefit for mothers and their fetuses.
Objective: The aim of this pilot non randomized control study was to use pravastatin +L-arginine to improve uteroplacental haemodynamics and prevent adverse maternal and neonatal outcomes in women with abnormal Dopplers and high risk for developing adverse pregnancy outcomes.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!